Showing papers on "Doxorubicin published in 1972"
TL;DR: Adriamycin appears to be effective therapy for disseminated osteogenic sarcoma, and the toxic reactions from its administration do not preclude the practical application of the drug in the treatment of this usually fatal neoplasm.
Abstract: Doxorubicin (adriamycin) is a new cytotoxic antibiotic with antitumor activity in a variety of neoplasms in man. Thirteen patients with pulmonary metastases from osteogenic sarcoma were given adriamycin at a dose ranging from 17.5 to 35 mg/sq m of body surface area daily for three or four days, repeated at monthly intervals. Of these, one patient had complete remission; three, partial remissions; and one improvement by 25% tumor regression was also obtained. Toxic manifestations of adriamycin administration were pancytopenia, capital alopecia and hair loss from other parts of the body, stomatitis, and nausea and vomiting. Adriamycin appears to be effective therapy for disseminated osteogenic sarcoma, and the toxic reactions from its administration do not preclude the practical application of the drug in the treatment of this usually fatal neoplasm.
124 citations
01 Jan 1972
TL;DR: Adriamycin in Mesenchymal Tumors and Leukemias - Results of Two Years' Research and Preliminary Clinical Observations on the Antitumor Effect of AdRIamycin.
Abstract: Short Summary of the Informal Meeting Preceeding the Adriamycin Symposium..- I. Chemistry of Adriamycin.- Structure and Physicochemical Properties of Adriamycin (Doxorubicin)..- II. Activity at Cell Level.- Effect of Adriamycin on the Cell Kinetic of Human Bone Marrow in vitro..- Ultrastructural Alterations Induced in Hepatic Cell Nucleoli by Adriamycin..- Effects of Adriamycin on Blastogenesis and Chromosomes of Blood Lymphocytes: "in vitro" and "in vivo" Studies..- Action of Adriamycin on HeLa Cells. Evidence of a G2 Inhibition..- III Activity against Experimental Tumors.- Adriamycin: The Therapeutic Activity on Experimental Tumors..- Some Factors Influencing the Chemotherapeutic Effectiveness of Adriamycin..- Antitumor Effects of Adriamycin on Yoshida Rat Sarcoma and L 1210 Mouse Leukemia - Cross-resistance and Combination Chemotherapy..- Cross-resistance between Adriamycin, Daunomycin and Vincristine in Ehrlich Ascites Tumor in vivo..- IV. Pharmacology and Pharmacokinetics.- Influence of Pharmacokinetic Variations on the Pharmacological Properties of Adriamycin..- Pharmacokinetics and Metabolism of Adriamycin and Daunomycin..- Blood Levels, Tissue Distribution and Clinical Effects of Adriamycin..- V. Clinical Activity and Side Effects.- Adriamycin in the Treatment of Acute Leukemia..- Clinical Trials with Adriamycin. Results of a Three-Years Study..- Clinical Trials of Adriamycin. E. Frei, III, J. K. Luce, and E. Middleman.- Preliminary Results of a Clinical Trial with Intermittent Doses of Adriamycin in Lung Cancer..- Adriamycin in Adults with Neoplastic Diseases. I. H. Krakoff.- Adriamycin in the Treatment of Acute Leukemias..- Cooperative Clinical Study on Adriamycin in Advanced Lung Tumors..- Adriamycin and Daunomycin in the Treatment of Vesical and Prostatic Neoplasias. Preliminary Results..- Clinical Trial of Adriamycin..- The Effect of Adriamycin on Solid Tumors and Acute Leukemia of Adults and Children..- Adriamycin in Children with Acute Leukemia and Other Neoplastic Diseases..- Adriamycin in the Treatment of Acute Leukemia..- VI. Short Communications.- Adriamycin in Mesenchymal Tumors and Leukemias - Results of Two Years' Research..- Preliminary Clinical Observations on the Antitumor Effect of Adriamycin..- Preliminary Clinical Trial of Adriamycin in Acute Leukemia and Solid Tumors of Children..- Combined Chemotherapy of Acute Leukemias..- Clinical Trial of Adriamycin on Malignant Diseases..- Adriamycin in the Chemotherapy of 21 Solid Tumors. Preliminary Results..- Adriamycin Use in Solid Tumors and in Lymphoblastic Leukemia of Children..- Preliminary Data on the Treatment of Hemoblastoses with Adriamycin..- Clinical Trials with Adriamycin..- Adriamycin, Vincristine and Prednisone in the Treatment of Malignant Tumors Resistant to Conventional Chemotherapy..
48 citations